
Opinion|Videos|December 23, 2025
Other Strategies Incorporating Percutaneous Hepatic Perfusion in Metastatic Uveal Melanoma
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss other ways percutaneous hepatic perfusion could be integrated into metastatic uveal melanoma management.
Advertisement
Episodes in this series

Prof.Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss additional ways percutaneous hepatic perfusion might be integrated into metastatic uveal melanoma management beyond the CHOPIN framework. They consider opportunities for pairing PHP with emerging systemic therapies, as well as its potential role earlier in the disease course. They Khan also address logistical and patient-selection considerations that could guide future adoption.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
3
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
4
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
5

